MariMed Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

MEZZANINE EQUITY (Details Narrative)

MEZZANINE EQUITY (Details Narrative) - USD ($)			1 Months Ended		3 Months Ended	6 Months Ended	9 Months Ended
MEZZANINE EQUITY (Details Narrative) - USD ($)	Oct. 31, 2020	Feb. 29, 2020	Mar. 31, 2021	Feb. 29, 2020	Mar. 31, 2021	Jun. 30, 2021	Sep. 30, 2021	Sep. 30, 2020
Stock Issued During Period, Shares, New Issues							109,308
Payments of Stock Issuance Costs	$ 100,000						$ 386,983
Proceeds from Issuance or Sale of Equity			$ 23,000,000.0
Payments for Construction in Process			$ 7,800,000
Targeted acquisition commitment description			The balance of the committed facility of up to an additional $23.0 million is intended to fund the Company’s specific targeted acquisitions provided such acquisitions are contracted in 2021 and consummated, including obtaining the necessary regulatory approvals, no later than the end of 2022. Such funds shall be provided by Hadron on the same aforementioned terms as the initial proceeds.
Warrants Two [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights							15,540,540
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 1.087
Fair Value Adjustment of Warrants					$ 9,500,000		$ 9,500,000
Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 0.55
Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 0.11
Hadron Healthcare Master Fund [Member] \| Warrants [Member]
Stock Issued During Period, Shares, New Issues			6,216,216
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 1.087		$ 1.087
Payments of Stock Issuance Costs			$ 387,000
Hadron Healthcare Master Fund [Member] \| Maximum [Member] \| Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			15,540,540		15,540,540
3M Note [Member]
Repayments of Debt and Lease Obligation						$ 15,200,000
Series B Convertible Preferred Stock [Member] \| Volume Weighted Average Price of Common Stock [Member]
Series B preferred stock conversion price, description		If the sixty-day VWAP is greater than $0.50 per share, the Company shall have the option		If the sixty-day VWAP is less than or equal to $0.50 per share, the Company shall have the option to (i) convert all shares of Series B convertible preferred stock into common stock at a conversion price of $1.00 per share, and pay cash to the Series B Holders equal to the difference between the 60-day VWAP and $3.00 per share, or (ii) pay cash to the Series B Holders equal to $3.00 per share.
Series B Holders [Member]
Shares Issued, Price Per Share		$ 3.00		$ 3.00
Preferred Stock, Convertible, Conversion Price		3.00		$ 3.00
Series C Convertible Preferred Stock [Member] \| Minimum [Member]
Outstanding percentage.			50.00%
Exchange Agreement [Member] \| Two Institutional Shareholders [Member] \| Series B Convertible Preferred Stock [Member]
Stock Issued During Period Shares Exchanged				4,908,333
Shares Issued, Price Per Share		$ 3.00		$ 3.00
Securities Purchase Agreement [Member] \| Hadron Healthcare Master Fund [Member]
Shares Issued, Price Per Share			$ 3.70		$ 3.70
Stock Issued During Period, Value, New Issues			$ 23,000,000.0
Warrants and Rights Outstanding, Term			4 years		4 years
Securities Purchase Agreement [Member] \| Hadron Healthcare Master Fund [Member] \| Maximum [Member]
Number of shares exchanged value.			$ 46,000,000.0